Please login to the form below

Not currently logged in
Email:
Password:

Pfizer and Mylan to market generic drugs in Japan

Will collaborate on portfolio of more than 350 existing products in expanding market

Pfizer and Mylan are to work together to develop, manufacture and market a range of generic drugs in Japan under the Pfizer brand.

The deal will involve a combined portfolio of more than 350 products across a range of therapeutic categories, as well as more than 125 additional products in development.

As part of the agreement, US-based generic firm Mylan will have responsibility for managing operations, including R&D and manufacturing, while Pfizer will handle commercialisation efforts and managing a combined sales and marketing team.

The companies will share costs and profits resulting from the collaboration, although specific terms are confidential. Both Mylan and Pfizer will also continue to operate independently in Japan.

The companies will also be looking to capitalise on a growing generics market in Japan, currently the sixth largest in the world and worth $5.2bn last year. The market is also poised for further growth, with the Japanese government aiming to increase the current volume of generic use from 24 per cent to 30 per cent by the end of 2012.

Further growth drivers for Japan's generics market will come from its aging population, patent expiries for major drugs and attempts to reduce healthcare spending.

This is in line with an expansion of the global generic drug market, which is due to increase in annual worth from $124bn in 2010 to $231bn by 2017.

Confirming these expectations Mylan's CEO Heather Bresch said: "We are very excited to have the opportunity to be partnering with Pfizer to build upon our existing assets and drive an even stronger, more sustainable generics business in Japan - one which will be well-positioned to take advantage of anticipated growth in generic utilisation in this market and other significant growth opportunities.”

23rd August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics